

Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 27 February 2021

Situation Report No. 240 - Kingdom of Bahrain
28th of February, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Total	113,076,707	2,512,272	6,360,314	144,138
New	1,282,206 in 3 days	30,932 in 3 days	93,577 in 3 days	1,150 in 3 days


Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	121,778	114,472	444	6,862	70	3,077,307
New	1,920 in 3 days	2,149 in 3 days	7 in 3 days	-	-	42,150 in 3 days


HIGHLIGHTS

- The mortality were: 6 Bahraini citizens (3 male (45, 76 and 81 years old) and 3 female (58, 67 and 77 years old)) and a 49 years old male expatriates.
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed that total number of individuals vaccinated as of 24 February 2021 is 295,296.
- Bahrain approved a fifth vaccine against the COVID-19 for emergency use, namely the single dose Johnson & Johnson Vaccine.
- The Ministry of Health announced that it opened COVID-19 vaccination registration for breastfeeding mothers and pregnant women.
- To increase vaccine efficiency, Covishield-AstraZeneca dosing intervals have been extended from 4 to 8 weeks.
- Based on advice of National Medical Taskforce for Combating the Coronavirus, the Ministry of Health extended COVID-19 precautionary measures for additional 3 months (until 31 May 2021).
- A BHD 20 Fine is imposed for not wearing a mask in public places.
- A 42-year-old male expatriate who tested positive for COVID-19 after arrival into Bahrain has infected 26 people.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassay; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises; see link below
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 vaccine placebo-controlled vaccine trials and trial unblinding; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health; see link below.
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing; see link below.
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum; see link below.
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers; see link below.
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19; see link below.
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum; see link below.
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines; see link below.
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020; see link below.
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021; see link below.
- WHO: Contact tracing in the context of COVID-19; see link below.
- WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19; see link below.
- WHO: COVID-19 Occupational health and safety for health workers; see link below.
- WHO: Weekly operational update on COVID-19 - 13 February 2021; see link below.
- WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out; see link below.
- WHO: 67 leaders commit US\$ 4.3 billion to finance global equitable access to tests, treatments and vaccines in 2021; see link below.
- WHO COVID-19 oxygen emergency impacting more than half a million people in low- and middle-income countries every day, as demand surges; see link below.


Number of New Cases



Total Number of Cases



Number of New Deaths



IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: https://www.who.int/docs/default-source/coronavirus/situation-reports/20200217-weekly-epi-update-1.pdf?sfvrsn=b6d49a76_4
- WHO's COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/2svb5dr>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: [https://www.who.int/publications/item/emergency-global-supply-chain-system-\(covid-19\)-catalogue](https://www.who.int/publications/item/emergency-global-supply-chain-system-(covid-19)-catalogue)
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: <https://bit.ly/2H0Vf>
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/2DmWV>
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises: <https://www.who.int/publications/item/9789240017447>
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/1066837553>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: <https://www.who.int/publications/item/WHO-2019-nCoV-EU-2020-01>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: <https://www.who.int/publications/item/WHO-2019-nCoV-Risk-Assessment-Tool-2020.1>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- WHO: Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health: <https://www.who.int/publications/item/9789240013440>
- WHO: Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing: https://www.who.int/publications/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1
- WHO: Global scientists double down on SARS-CoV-2 variants research at WHO-hosted forum: <https://www.who.int/news/item/12-01-2021-global-scientists-double-down-on-sars-cov-2-variants-research-at-who-hosted-forum>
- WHO: Analysing and using routine data to monitor the effects of COVID-19 on essential health services: practical guide for national and subnational decision-makers: https://www.who.int/publications/item/WHO-2019-nCoV-essential_health_services-monitoring-2021.1
- WHO: Background document on mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19: [https://www.who.int/publications/item/background-document-on-mrna-vaccine-bnt162b2-\(pfizer-biontech\)-against-covid-19](https://www.who.int/publications/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19)
- WHO: Scientists tackle vaccine safety, efficacy and access at global R&D forum: <https://www.who.int/news/item/16-01-2021-scientists-tackle-vaccine-safety-efcacy-and-access-at-global-r-d-forum>
- WHO: Emergency Committee on COVID-19 advises on variants, vaccines: <https://www.who.int/news/item/15-01-2021-emergency-committee-on-covid-19-advises-on-variants-vaccines>
- WHO: Online global consultation on contact tracing for COVID-19, 9-11 June 2020: <https://www.who.int/publications/item/online-global-consultation-on-contact-tracing-for-covid-19-9-11-june-2020>
- WHO: COVID-19 Virtual Press conference transcript - 1 February 2021: <https://www.who.int/news/item/25-02-2021-covid-19-virtual-press-conference-transcript-1-february-2021>
- WHO: Contact tracing in the context of COVID-19: <https://www.who.int/publications/item/contact-tracing-in-the-context-of-covid-19>
- WHO: Background document on the mRNA-1273 vaccine (Moderna) against COVID-19: [https://www.who.int/publications/item/background-document-on-the-mrna-1273-vaccine-\(moderna\)-against-covid-19](https://www.who.int/publications/item/background-document-on-the-mrna-1273-vaccine-(moderna)-against-covid-19)
- WHO: COVID-19 Occupational health and safety for health workers: https://www.who.int/publications/item/WHO-2019-nCoV-HCW_advice-2021.1
- WHO: Weekly operational update on COVID-19 - 13 February 2021: <https://www.who.int/publications/item/weekly-operational-update-on-covid-19-13-february-2021>
- WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out: <https://www.who.int/news/item/15-01-2021-who-lists-two-additional-covid-19-vaccines-for-emergency-use-and-covax-roll-out>
- WHO: 67 leaders commit US\$ 4.3 billion to finance global equitable access to tests, treatments and vaccines in 2021: <https://www.who.int/news/item/19-02-2021-g7-leaders-commit-us-4.3-billion-to-finance-global-equitable-access-to-tests-treatments-and-vaccines-in-2021>
- WHO COVID-19 oxygen emergency impacting more than half a million people in low- and middle-income countries every day, as demand surges: <https://www.who.int/news/item/25-02-2021-covid-19-oxygen-emergency-impacting-more-than-half-a-million-people-in-low-and-middle-income-countries-every-day-as-demand-surges>

IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: NAIi5@health.gov.bh
- International Health Regulations focal person is Dr. Kubra Salman, email: knasser@health.gov.bh